ON：2026-1-04 TAGS：GLUETACS THERAPEUTICS

On January 4, 2026, Gluetacs Therapeutics, an innovative clinical-stage biopharmaceutical company specializing in targeted protein degradation, announced that it will attend the 44th Annual J.P. Morgan Healthcare Conference and present at the Biotech Showcase Healthcare Investor Conference taking place in San Francisco from January 12–15, 2026. James Mao, Head of Global Business Development, will attend and present a company presentation at the Biotech Showcase on January 14, 2026 at 4:15 PM PST to share the latest development of targeted protein degradation technology platform and preliminary results of clinical and pre-clinical pipelines, and explore opportunities for collaboration.

Biotech Showcase™, is a dedicated investor conference designed to provide private and micro-mid-cap biotechnology companies with the opportunity to present to and connect with investors and biopharmaceutical executives. With a roster of over 400 carefully selected presenting companies from across the globe, ranging from seed-stage startups to established multinational corporations, encompassing diverse fields such as platform technologies, therapeutic areas, digital health, devices, and diagnostics, these events attract investors wielding over USD 400 billion in capital and motivated strategic partners within the life science ecosystem.

Gluetacs cordially invites you to interact with us at J.P. Morgan Healthcare Conference and the Biotech Showcase 2026. You can contact us via Website/Online Appointment System and E-mail and meet our team at the conference.

Biotech Showcase 2026 Website/Online Appointment System: 

https://informaconnect.com/biotech-showcase/partnering

Contact us：

james.mao@gluetacs.com; bd@gluetacs.com